Cvijic Christine Mikail 4
4 · Neurogene Inc. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) President/CFO Christine Cvijic Sells Shares
What Happened
- Christine Cvijic, President and Chief Financial Officer of Neurogene, reported the sale of 2,558 shares on March 26, 2026. The shares were sold at a weighted-average price of $21.62 for total proceeds of $55,316. This transaction was a sale performed to satisfy tax withholding obligations arising from partial vesting of a restricted stock unit (RSU) award, not an independent open-market investment decision.
Key Details
- Transaction type: Sale (S); transaction date: 2026-03-26; filing date: 2026-03-30 (timely within the Form 4 two-business-day window).
- Price: weighted average $21.62; individual sale prices ranged from $21.10 to $21.91. Reporting person can provide per-price breakdown on request (footnote F2).
- Reason: Mandatory share sale to cover tax withholding on RSU vesting (footnote F1). The award agreement requires the company to sell sufficient shares to cover the withholding; the reporting person did not make an election to retain shares.
- Holdings/awards noted (footnote F3): remaining unvested RSUs include 10,635 (granted 3/13/2024, vest 3/13/2027), 13,533 (granted 3/26/2025, vesting in equal installments 3/26/2027 & 3/26/2028), and 22,000 (granted 2/20/2026, vesting in equal installments 2/20/2027–2/20/2029). Additionally, 19,200 shares are held jointly with spouse David Cvijic.
- Filing timeliness: Filed March 30, 2026 for a March 26 transaction — appears timely under Section 16 rules.
Context
- This sale was a mandatory, tax-withholding sale tied to RSU vesting (routine administrative sale), which is different from a discretionary insider sale that might signal a change in sentiment. Retail investors typically view mandated withholding sales as neutral rather than a negative signal about company prospects.
Insider Transaction Report
Form 4
Neurogene Inc.NGNE
Cvijic Christine Mikail
DirectorPresident and CFO
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-26$21.62/sh−2,558$55,316→ 103,240 total
Footnotes (3)
- [F1]On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Signature
/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic|2026-03-30